Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
US10709775B2 · kind B2 · utility
5Cited by
0References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 26, 2016 |
| Grant date | Jul 14, 2020 |
| Priority date | — |
| Expiry date | Jul 26, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.